Please assess the completion status of the following clinical trial:

Trial Title: Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Female participants must be postmenopausal, surgically sterile, or if premenopausal, be prepared to use 1 effective method of contraception with all sexual partners during the study and for 14 days after the end of dosing.~* Male participants must be prepared to use 1 effective method of contraception with all sexual partners during the study during the study unless they had a prior vasectomy.~* Proven or likely PBC, as demonstrated by the participant presenting with at least 2 of the following 3 diagnostic factors:~* History of increased alkaline phosphatase (ALP) levels for at least 6 months;~* Positive antimitochondrial antibody titer (\>1:40 titer on immunofluorescence or M2 positive by enzyme-linked immunosorbent assay) or PBC-specific antinuclear antibodies (antinuclear dot and nuclear rim positive);~* Liver biopsy consistent with PBC~* Screening ALP level between 1.5 and 10 × upper limit of normal (ULN).~Exclusion Criteria:~* Administration of the following drugs at any time during the 3 months prior to screening for the study: ursodeoxycholic acid, colchicine, methotrexate, azathioprine, or systemic corticosteroids.~* Screening conjugated (direct) bilirubin \>2 × ULN.~* Screening alanine aminotransferase or aspartate aminotransferase \>5 × ULN.~* Screening serum creatinine \>133 micromoles/liter (1.5 mg/deciliter).~History or presence of hepatic decompensation (for example, variceal bleeds, encephalopathy, or poorly controlled ascites).~* History or presence of other concomitant liver diseases including hepatitis due to hepatitis B or C virus infection, primary sclerosing cholangitis, alcoholic liver disease, definite autoimmune liver disease or biopsy proven nonalcoholic steatohepatitis.~* Pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- DB OCA 10 mg (Type: EXPERIMENTAL): OCA 10 mg for 3 months during the DB phase.
- DB OCA 50 mg (Type: EXPERIMENTAL): OCA 50 mg for 3 months during the DB phase.
- DB OCA Placebo (Type: PLACEBO_COMPARATOR): Matching placebo for 3 months during the DB phase.
- LTSE OCA Total (Type: EXPERIMENTAL): After completion of the 3-month DB phase, all eligible participants were offered the opportunity to enter an open-label LTSE for up to 96 months beginning at 10 mg OCA. Doses up to 50 mg daily were evaluated.

Based on this trial design, predict the completion outcome and termination type (if applicable).